Glucocorticoid use in myasthenia gravis patients increases fracture risk by reducing bone density and weakening bone structure. Combining FRAX and MG-ADL scales enhances the identification of ...

Please provide your email address to receive an email when new articles are posted on . Researchers calculated the likelihood of achieving a BMD T-score of –2.5 or higher with denosumab based on ...

You turned 65, got your Medicare card, and scheduled your annual checkup. But there’s a screening many doctors forget to mention, even though every woman 65 and older should have one. The bone density ...

Patients with glucocorticoid-induced osteoporosis on romosozumab show greater gains in lumbar spine bone mineral density than those on denosumab and comparable gains with those on teriparatide.